

Special Issue

Soft and Hard Tissue Sarcoma –Current and Future Concepts in Diagnosis and Treatment

Message from the Guest Editor

Despite being relatively rare tumors, soft and hard tissue sarcomas contribute to a significant number of patients needing treatment. Diagnostic and treatment concepts for soft and hard tissue sarcomas have advanced in recent years. In this review, established and recently developed diagnostic tools, ranging from new immunohistochemical markers and genetic profiling to liquid biopsies and mRNA-based diagnostics in sarcomas, will be elucidated. Surgery is the first line of treatment in many sarcoma cases, comprising orthopedic surgery, plastic surgery, as well as general and visceral surgery, often in an interdisciplinary approach. Hence, current concepts for surgical treatment of soft and hard tissue sarcomas of the trunk and extremities, as well as reconstructive options, will be in the focus of the surgical contributions to this Special Issue. In summary, the aim of this Special Issue is to highlight recent studies on sarcoma diagnostics, medical and surgical sarcoma treatment, including reconstructive surgery, and future perspectives based on experimental models for sarcoma research.

Guest Editor

Prof. Dr. Justus P. Beier

Department of Plastic Surgery, Hand Surgery - Burn Center, University Hospital RWTH Aachen, Pauwelsstr. 30, 52074 Aachen, Germany

Deadline for manuscript submissions

closed (10 April 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/90786

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)